🇺🇸 FDA
Pipeline program

EPI-7386, Xtandi - 40 mg soft capsules

EPI-7386-CS-010

Phase 2 small_molecule active

Quick answer

EPI-7386, Xtandi - 40 mg soft capsules for Metastatic castration-resistant prostate cancer is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Metastatic castration-resistant prostate cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials